Trial Profile
The evaluation of oxidative stress and the effect of pirfenidone in patients with idiopathic pulmonary fibrosis.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2020
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- 23 Apr 2020 Status changed from recruiting to discontinued.
- 01 Apr 2015 New trial record